21 CFR 862.3645
§ 862.3645 Neuroleptic drugs radioreceptor assay test system.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 862.3645, § 862.3645 Neuroleptic drugs radioreceptor assay test system, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/89278
- Permanent ID
ys:prov:89278@1- SHA-256
30018d08d36716c3ff98ae0db28a52bc829a46cfea6a0d6875eb5e4fd054cccc
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Identification. A neuroleptic drugs radioceptor assay test system is a device intended to measure in serum or plasma the dopamine receptor blocking activity of neuroleptic drugs and their active metabolites. A neuroleptic drug has anti-psychotic action affecting principally psychomotor activity, is generally without hypnotic effects, and is a tranquilizer. Measurements obtained by this device are used to aid in determining whether a patient is taking the prescribed dosage level of such drugs.
(b) Classification. Class II.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.